ReviewAntiviral therapy2012
Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?
Review in Antiviral therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 65 citations in OpenAlex.
- In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450.Antimicrobial agents and chemotherapy · 2015Trial
- A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.Antiviral therapy · 2015Trial
- Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.Antimicrobial agents and chemotherapy · 2014Trial
- Review
- Article
- Mathematical modeling of hepatitis C RNA replication, exosome secretion and virus release.PLoS computational biology · 2020Article
- Article
- Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations.Infection and drug resistance · 2019Article
- Intracellular Hepatitis C Virus Modeling Predicts Infection Dynamics and Viral Protein Mechanisms.Journal of virology · 2018Article
- Strategies to control HIV and HCV in methadone maintenance treatment in Guangdong Province, China: a system dynamic modeling study.Substance abuse treatment, prevention, and policy · 2018Article
- Modeling Viral Spread.Annual review of virology · 2016Review
- A review of disease progression models of Parkinson's disease and applications in clinical trials.Movement disorders : official journal of the Movement Disorder Society · 2016Review
- Modelling the prevalence of hepatitis C virus amongst blood donors in Libya: An investigation of providing a preventive strategy.World journal of virology · 2016Article
- Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies.Journal of pharmacokinetics and pharmacodynamics · 2015Article
- Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection.Hepatology (Baltimore, Md.) · 2015Article
- Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response.The Journal of infectious diseases · 2014Article
- Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.Hepatology (Baltimore, Md.) · 2014Article
- Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes.PLoS computational biology · 2014Article
- Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs.Theoretical biology & medical modelling · 2014Article
- Quantification of viral infection dynamics in animal experiments.Frontiers in microbiology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
HCV infection is a major cause of chronic liver disease and affects nearly 170 million people worldwide. Whereas the previous standard of care with pegylated interferon and ribavirin had a modest effectiveness, the recent approval of two highly potent protease inhibitors and the ongoing development of dozens of direct-acting antiviral agents (DAAs) constitute a major milestone for HCV therapy. Mathematical modelling of viral kinetics under treatment has played an instrumental role in improving our understanding of virus pathogenesis and in guiding drug development. Here, we review the current state of HCV kinetic modelling, and challenges to the standard biphasic viral decline model that arise when fitting viral kinetic models to data obtained with DAAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.